Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Added to Russell 1000 and Russell 3000 Indexes

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen today said that its common stock has been added to the US large-cap Russell 1000 Index and the broad market Russell 3000 Index.

Russell Investments reconstituted its equity indexes after the close of the market on Friday, resulting in Qiagen's inclusion, the molecular diagnostics and sample prep technologies firm said.

The Russell 3000 Index measures the performance of the 3,000 largest companies in the US and represents roughly 90 percent of the investible US equity market. The Russell 1000 Index represents the highest-ranking 1,000 companies in the US.

"This inclusion provides further support and liquidity for Qiagen's common shares, and thereby more benefits to participating in Qiagen's growth and creation of value for shareholders,” Qiagen CEO Peer Schatz said in a statement.

In early afternoon trading today on Nasdaq, shares of Qiagen were up 1 percent at $18.89.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.